HDAC9 and idiopathic pulmonary fibrosis: In conclusion, the published findings summarised in this review indicate that HDACs offer novel molecular targets for IPF therapy and that FDA-approved Class I and pan-HDAC inhibitors for cancer treatment may also be promising therapeutic agents for the treatment of IPF.